A 72-year-old man with severe COPD (FEV₁ 38% predicted), frequent exacerbations and persistent dyspnoea despite a long-acting muscarinic antagonist (LAMA) presents to clinic. He continues to smoke 10 cigarettes per day. According to the 2023 CTS COPD pharmacotherapy guideline, what is the most appropriate next escalation of inhaled therapy?